In December, data from the Phase 2a trial of PTX-200 in 11 women with HER-2 negative breast cancer showed an overall response rate of 91 per cent, with nine of 10 patients being monitored for cancer remaining progression-free, with encouraging ongoing durability of response.
That clarifies that the data is from the December set. But that patent to 2025 is still same. So looks like not a typo. In view of that, why bother with that patent which would have probably expired even before the product is out there in earnest!
PTX Price at posting:
6.0¢ Sentiment: Hold Disclosure: Held
